# US biotech Q2 earnings reports

> Live situation record from CLSTR: https://clstr.news/situations/us-biotech-q2-earnings-reports
> Updated: 2026-08-04T20:04:28.000Z. Sources: 12. Developments: 2.

In late July 2026 Biogen posted a modest 3% year‑over‑year revenue rise to $2.7 billion, driven by its multiple‑sclerosis drugs and newer products such as Skyclarys and Leqembi. A week later Amgen reported stronger Q2 performance, with revenue up 9% to $10.1 billion and earnings per share beating expectations, while Gilead Sciences announced an 8% increase in product sales to $7.8 billion, led by double‑digit growth in its HIV portfolio.

On 4 August 2026 Amgen confirmed its 9% sales growth, posted adjusted earnings of $6.29 per share, and raised its full‑year earnings outlook to $22.30‑$23.50 per share on revenue of $38.2‑$39.4 billion. The company also disclosed the discontinuation of its obesity drug candidate AMG 513. Gilead reiterated its adjusted loss of $6.75 per share, better than forecasts, and highlighted continued strength in HIV, liver‑disease, and oncology segments.

Other biotech peers reported mixed results: Geron recorded a Q2 loss of $16.7 million on $57.5 million revenue, driven by its oncology drug RYTELO; Rigel Pharmaceuticals earned $0.88 per share, beating expectations, with $67 million in commercial revenue; Precigen posted a modest EPS beat of $0.05 on $55 million revenue; and TG Therapeutics saw BRIUMVI sales jump 64% to $227.7 million. The series of reports underscores a broadly healthy earnings environment for major U.S. biotech firms in the second quarter of 2026.

## Claims

- Amgen's second-quarter sales rose 9% to $10.1 billion. (corroborated by 4 sources)
- Amgen's adjusted earnings per share were $6.29, beating expectations of $5.62. (corroborated by 4 sources)
- Amgen's net earnings per share increased 65% to $4.37. (corroborated by 4 sources)
- Amgen raised its full‑year earnings outlook to $22.30‑$23.50 per share on revenue of $38.2‑$39.4 billion. (corroborated by 4 sources)
- Quarterly sales of Repatha were $953 million, up 37% YoY. (corroborated by 4 sources)
- Quarterly sales of Evenity were $714 million, up 38% YoY. (corroborated by 4 sources)
- Sales of Uplizna increased 90% to $335 million. (corroborated by 4 sources)
- Amgen discontinued development of obesity candidate AMG 513. (corroborated by 4 sources)
- Gilead Sciences' second‑quarter sales rose 8% to $7.8 billion, beating the $7.4 billion estimate. (single source)
- Gilead's adjusted loss per share was $6.75, better than the $7.24 expected. (single source)
- TG Therapeutics' BRIUMVI revenue jumped 64% to $227.7 million in Q2 2026. (single source)

## Timeline

### 2026-08-04: Amgen posts 9% Q2 sales growth and earnings beat as biotech peers report results

Amgen posted 9% Q2 sales growth to $10.1 bn, earnings beat and raised outlook; Gilead posted 8% sales rise, other biotech firms reported mixed Q2 results.

10 sources. https://clstr.news/cluster/amgen-posts-9-q2-revenue-growth-earnings-exceed-forecasts

### 2026-07-29: Biogen posts strong Q2 earnings as Australian biotech firms report solid quarterly results

Biogen beats Q2 forecasts with $2.7 bn revenue, while Australian biotech firms Mesoblast, Actinogen and Alterity report solid earnings and cash positions.

2 sources. https://clstr.news/cluster/biogen-posts-strong-q2-earnings-as-australian-biotech-firms-report-solid-quarterly-results

---
Cite as: US biotech Q2 earnings reports. CLSTR, https://clstr.news/situations/us-biotech-q2-earnings-reports